Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.
NCT04181359 · University of Alberta · PHASE1/PHASE2 · withdrawn · last registry update 2024-09-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was no longer feasible as designed.” | – | Registry record, University of Alberta |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GUCY1B1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-17Also stopped (withdrawn): Ruijin Hospital, Oral isosorbide mononitrate 4+ amlodipine (NCT06730945)
- 2025-08-20Also stopped (terminated): Montefiore Medical Center, a drug against GUCY1B1 (NCT03026101)
- 2025-08-03Also stopped (terminated): Queen Mary University of London, a drug against GUCY1B1 (NCT03511248)
- 2025-07-15Results posted on the registry: Thirty Respiratory Limited, RESP301 + HRZE (NCT06041919)
- 2025-07-15Also stopped (terminated): Thirty Respiratory Limited, RESP301 + HRZE (NCT06041919)
- 2025-06-08Results posted on the registry: Western Sydney Local Health District, a drug against GUCY1B1 (NCT05401409)
- 2025-06-03Phase 3 first posted: Kardigan, Inc., Ataciguat + Placebo (NCT07001800)
- 2025-05-25Phase 3 first posted: Asklepion Pharmaceuticals, LLC, L-citrulline (NCT06989567)
- 2025-05-11Results posted on the registry: Peng Roc Chen, MD, Nicardipine + Verapamil (NCT01996436)
- 2025-05-11Also stopped (terminated): Peng Roc Chen, MD, Nicardipine + Verapamil (NCT01996436)
- 2025-05-04Results posted on the registry: Lacy Alexander, a drug against GUCY1B1 (NCT03376555)
- 2025-04-30Results posted on the registry: University of Cincinnati, Inhaled Nitric Oxide + Placebo (NCT03260569)
- 2025-04-23Results posted on the registry: Vicore Pharma AB, C21 + Sodium Nitroprusside (NCT05277922)
- 2025-04-10Phase 3 first posted: Suqiao Yang, Riociguat + Routine Treatment (NCT06922240)
- 2025-04-08Also stopped (terminated): Colorado State University, Acetylcholine + Sodium Nitroprusside (NCT04001647)
- 2025-04-04Phase 3 first posted: University of Medicine and Pharmacy "Victor Babes" Timisoara, Nitroglycerin transdermal (NCT06912139)
- 2025-02-19Results posted on the registry: Indiana University, a drug against GUCY1B1 (NCT03513302)
- 2025-02-04Also stopped (terminated): Actelion, Bosentan + Matching placebo (NCT01389856)
- 2025-01-31Results posted on the registry: Thirty Respiratory Limited, RESP301 (NCT04858451)
- 2025-01-31Also stopped (terminated): Thirty Respiratory Limited, RESP301 (NCT04858451)
- 2025-01-21Phase 3 first posted: Beni-Suef University, Inhaled nitroglycerin (NCT06785337)
- 2025-01-20Results posted on the registry: University of Nebraska, Stellate Ganglion Block (NCT04445337)
- 2025-01-20Also stopped (terminated): University of Nebraska, Stellate Ganglion Block (NCT04445337)
- 2025-01-15Results posted on the registry: AdventHealth, inhaled nitric oxide + Placebo (NCT03576885)
- 2025-01-15Also stopped (terminated): AdventHealth, inhaled nitric oxide + Placebo (NCT03576885)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision